Inhibikase Therapeutics Inc美股招股说明书(2025-11-21版)

Pre-FundedWarrants to Purchase up to 22,873,779 Shares of Common Stock We are offering 46,091,739 shares of our common stock and, in lieu of common stock to investors that so choose,pre-fundedwarrants topurchase up to 22,873,779 shares of common stock. The purchase price of eachpre-fundedwarrant will equal the price per share atwhich shares of our common stock are being sold to the public in this offering, minus $0.001, which is the exercise price of eachpre-fundedwarrant. Thepre-fundedwarrants do not expire, and eachpre-fundedwarrant will be exercisable at any time after the date of Our common stock is listed on the Nasdaq Capital Market under the symbol “IKT.” On November19, 2025, the closing sale price of ourcommon stock on the Nasdaq Capital Market, was $1.56 per share. There is no established public trading market for thepre-fundedwarrants, and we do not expect a market to develop. We do not intend to list thepre-fundedwarrants on the Nasdaq Capital Market or any Investing in our securities involves a high degree of risk. Please read “Risk Factors” beginning on pageS-7of this prospectussupplement, page 2 in the accompanying prospectus, and under similar headings in the documents that are incorporated byreference herein and therein concerning factors you should carefully consider before investing in our securities. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities, or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Anyrepresentation to the contrary is a criminal offense. We are an “emerging growth company” and a “smaller reporting company” as defined under federal securities laws, and, as such, will be subjectto reduced public company reporting requirements for this prospectus supplement and future filings. See the section titled “Prospectus Summary—Implications of Being anEmerging Growth Companyand a Smaller Reporting Company.” Jefferies Cantor Oppenheimer & Co. ABOUT THIS PROSPECTUS SUPPLEMENTCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTSPROSPECTUS SUPPLEMENT SUMMARYRISK FACTORSDIVIDEND POLICYUSE OF PROCEEDSDILUTION DESCRIPTION OF DEBT SECURITIES DESCRIPTION OF WARRANTS PLAN OF DISTRIBUTION Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement is part of a registration statement on FormS-3(FileNo.333-288213)that we filed with the Securities and ExchangeCommission (the “SEC”), utilizing a “shelf” registration process. Under this shelf registration process, we may from time to time sell anycombination of the securities described in this prospectus supplement and accompanying prospectus in one or more offerings for an aggregateoffering price of up to $300,000,000. This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of common stockandpre-fundedwarrants. The second part is the accompanying prospectus, which provides more general information, some of which may notapply to this offering. The information included or incorporated by reference in this prospectus supplement also adds to, updates and changesinformation contained or incorporated by reference in the accompanying prospectus. If information included or incorporated by reference in thisprospectus supplement is inconsistent with the accompanying prospectus or the information incorporated by reference therein, then thisprospectus supplement or the information incorporated by reference in this prospectus supplement will apply and will supersede the information in Before buying any of the shares of common stock orpre-fundedwarrants offered hereby, we urge you to read carefully this prospectussupplement and the accompanying prospectus, together with the information incorporated herein by reference as described below under theheading “Incorporation of Certain Information by Reference,” as well as the additional information described in this prospectus supplement under We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document thatis incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose ofallocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover,such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and Neither we nor the underwriters have authorized anyone to provide you with information other than the information that we have provided orincorporated by reference in this prospectus supplement and the accompanying prospectus and your reliance on any unauthorized information orrepresentation is at your own risk. You should assume that the information appearing in this prospec